Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Trading Update

28 Jan 2015 07:00

RNS Number : 3154D
Sopheon PLC
28 January 2015
 



28 January 2015

 

SOPHEON PLC

 

("Sopheon", the "Group" or the "Company")

 

TRADING UPDATE

 

Sopheon plc, the international provider of software and services for complete Enterprise Innovation Performance solutions, announces initial indications of the Group's performance in 2014.

 

Revenues for the year ended 31 December 2014 are expected to be in the region of $18m, compared to reported revenues for 2013 of approaching $21m. Costs have been managed tightly and it is expected that the Group will continue to show a positive EBITDA result, albeit substantially lower than the approximately $3m achieved in 2013. In December, we noted that a number of material transactions we were expecting to conclude during the year were deferred to 2015. Activity towards the end of the year remained high, with 10 license transactions in December alone. We have entered 2015 with a recurring revenue base at approximately $8m, and committed services of approximately $2m. During the year, we have continued to penetrate our key markets, including business from market leaders such as BASF, PepsiCo and Bayer MaterialScience. Furthermore, all the very large deals that were in play at year end continue to be actively pursued in the current year.

 

As noted in our December announcement, we have continued to push forward with operational and corporate developments alongside business development. Our commercial team was strengthened with the hire of Pieter Leijten, formerly of Infor, to lead European sales. We released version 9.2 of our Accolade solution suite, which we believe provides the most comprehensive resource and portfolio planning and management capabilities in the market. Our rapid pace of product enhancement continues, with the release of version 9.3 expected in February. Alongside 9.3 will be the first iteration of our new Accolade Express offering, which will enable enterprises to rapidly automate innovation processes, based on implementing out-of-the-box best practices rooted in Sopheon's extensive experiences with industry leading customers. On the corporate side, we successfully completed our share consolidation and subdivision, which we believe has reduced Sopheon's shareholder base from around 12,000 when we first embarked on this process to under 2,000 today. As part of that process, Sopheon's board stood behind fractional entitlements that were sold on the market and purchased the equivalent of 471,500 current ordinary shares, emphasizing their belief in the Company's prospects.

 

Financial expectations noted above are subject to the completion of year-end financial close and audit processes. Sopheon plans to issue results for the year ended 31 December 2014 on 19 March 2015.

 

Barry Mence, Chairman, commented:

"Although we did close ten license transactions in December, we are disappointed with the way key deals deferred into 2015. We remain confident of the strategic path we are following and look for better commercial progress in the coming year, to match and leverage the major strides made in the last year with product and corporate matters."

 

 

For further information contact:

Barry Mence, Chairman

Sopheon plc

+ 44 (0) 1483 685 735

Arif Karimjee, CFO

Sopheon plc

+ 44 (0) 1483 685 735

Charlotte Stranner / Victoria Bates

finnCap

+ 44 (0) 20 7600 1658

Tim Thompson / Heather Armstrong / Ed Treadwell

Newgate Threadneedle

+ 44 (0) 20 7653 9842

Claire Verhagen

Citigate First Financial

+ 31 (0) 205 754 010

 

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Performance solutions including software, expertise, and best-practices to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade® solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle. For the first time, businesses can access a single source of the truth across strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange, and on the Alternext Exchange in the Netherlands. For more information, please visit www.sopheon.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLDLLLEFFBBBK
Date   Source Headline
6th Dec 20137:00 amRNSDirector/PDMR Shareholding
5th Dec 20137:00 amRNSCorporate Update
19th Nov 20137:00 amRNSSopheon Delivers Accolade® Release 9.0
7th Nov 20137:00 amRNSInterim Management Statement
11th Sep 20133:00 pmRNSHolding(s) in Company
4th Sep 20133:00 pmRNSHolding(s) in Company
22nd Aug 20137:00 amRNSInterim Results
15th Aug 20133:00 pmRNSHolding(s) in Company
29th Jul 20133:00 pmRNSHolding(s) in Company
26th Jul 20137:00 amRNSTrading Update
15th Jul 20134:15 pmRNSHolding(s) in Company
28th Jun 20133:00 pmRNSTotal Voting Rights
27th Jun 20133:00 pmRNSHolding(s) in Company
19th Jun 20133:42 pmRNSHolding(s) in Company
19th Jun 20137:00 amRNSNew capabilities with Accolade(R) 8.3
14th Jun 20132:00 pmRNSContract Win
12th Jun 201312:00 pmRNSResult of AGM & GM
12th Jun 20137:00 amRNSAGM Statement
4th Jun 20137:00 amRNSIssue of Shares
2nd May 20137:00 amRNSInterim Management Statement
21st Mar 20137:00 amRNSPreliminary Results
30th Jan 20137:00 amRNSTrading Update
23rd Jan 20137:00 amRNSLaunch of Accolade 8.2
7th Dec 201211:36 amPRNHolding(s) in Company
8th Nov 20127:00 amPRNInterim Management Statement
1st Oct 20127:00 amRNSHolding(s) in Company
1st Oct 20127:00 amRNSDirectors' Options
24th Sep 20127:00 amRNSMarket Transfer to NYSE Alternext Concluded
23rd Aug 20127:00 amRNSAmendment to Terms of Convertible Loan Stock
23rd Aug 20127:00 amRNSInterim Results
23rd Jul 20127:00 amRNSTrading Update
13th Jun 20123:14 pmRNSResult of AGM
13th Jun 20127:00 amRNSAGM Statement
15th May 20127:00 amRNSAmendment to terms of Convertible Loan Stock
3rd May 20127:00 amRNSInterim Management Statement
25th Apr 20127:00 amRNSLaunch of Accolade 8.0
22nd Mar 20127:00 amRNSPreliminary Results
16th Feb 20127:00 amRNSTop 10 Solution Provider to CGM
31st Jan 20127:00 amRNSTrading Update
23rd Dec 201112:32 pmRNSExtension of GEM Equity Line
23rd Dec 201112:29 pmRNSTrading Update
5th Dec 201112:40 pmRNSHolding(s) in Company
3rd Nov 20117:00 amRNSInterim Management Statement
25th Aug 20117:00 amRNSInterim Results
25th Jul 20117:00 amRNSTrading Statement
23rd Jun 20112:15 pmRNSDirector/PDMR Shareholding
15th Jun 20117:00 amRNSAGM Statement
5th May 20117:00 amRNSInterim Management Statement
24th Mar 20117:00 amRNSPreliminary Results
10th Feb 20117:00 amPRNAppointment of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.